SHPH · Insider Trading
Shuttle Pharmaceuticals Holdings, Inc. Common Stock
Every open-market purchase and sale reported by SHPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-15 | HRT FINANCIAL LP | 10%+ Owner | Sell | −83,149 | −$372.70K |
| 2026-07-13 | HRT FINANCIAL LP | 10%+ Owner | Buy | +8,997 | +$30.21K |
| 2026-07-09 | HRT FINANCIAL LP | 10%+ Owner | Sell | −29,111 | −$100.46K |
| 2026-07-07 | HRT FINANCIAL LP | 10%+ Owner | MIXED | −1,171 | −$3.87K |
| 2026-07-02 | HRT FINANCIAL LP | 10%+ Owner | Buy | +3,959 | +$13.06K |
| 2026-07-01 | HRT FINANCIAL LP | 10%+ Owner | Buy | +32,591 | +$110.69K |
| 2025-08-13 | Steven M Richards | Director | A | +29,240 deriv. | — |
| 2025-08-12 | George Scorsis | Director | A | +29,240 deriv. | — |
| 2025-08-12 | Joseph Tung | Director | A | +29,240 deriv. | — |
| 2025-08-12 | Timothy J. Lorber | Chief Financial Officer | A | +54,094 deriv. | — |
| 2025-08-12 | Oleh Nabyt | Director | A | +29,240 deriv. | — |
| 2024-10-09 | Mira Jung | Chief Scientific Officer | A | −598 | −$6.75K |
| 2024-03-14 | Chris Senanayake | Director | Sell | −1,626 | −$2.61K |
| 2024-03-08 | Michael Vander Hoek | Chief Financial Officer | A | +100,000 | — |
| 2024-01-02 | Milton Brown | Director | Sell | −2,921 | −$1.35K |
| 2023-12-20 | Bette Jacobs | Director | Sell | −4,157 | −$1.93K |
| 2023-08-18 | Anatoly Dritschilo | CEO and Chairman | G | — | — |
| 2023-02-17 | Milton Brown | Director | A | +25,000 deriv. | — |
| 2023-01-09 | Steven M Richards | Director | Sell | −995 | −$1.60K |
| 2023-01-04 | Milton Brown | Director | Sell | −995 | −$1.60K |
| 2023-01-04 | William Adkins | — | Sell | −995 | −$1.60K |
| 2023-01-03 | Tyvin Rich | Chief Medical Officer | Sell | −1,414 | −$2.27K |
| 2023-01-03 | Bette Jacobs | Director | Sell | −4,366 | −$7.01K |
| 2023-01-03 | Mira Jung | Chief Scientific Officer | Sell | −328 | −$526 |
| 2023-01-03 | Anatoly Dritschilo | CEO and Chairman | Sell | −8,372 | −$13.44K |
| 2022-12-30 | Michael Vander Hoek | Chief Financial Officer | Sell | −2,243 | −$3.60K |
| 2022-12-30 | Peter Dritschilo | President and COO | Sell | −3,820 | −$6.13K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| HRT FINANCIAL LP | 10%+ Owner | 60,238 | $303.90K |
| Steven M Richards | Director | 1 | $5 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SHPH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.